Mesoblast Ltd.
(NASDAQ: MESO)
|
8:00 PM UTC, 10/17/24 | |||
---|---|---|---|---|
Last: $9.93 | Change: +0.52 | %Change: +5.53% | Volume: 205,843 |
Open: | $ 9.75 | Volume: | 205,843 | |
---|---|---|---|---|
High: | $ 10.30 | Yield(%) | 0.00 | |
Low: | $ 9.73 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 1.07B | |
EPS ($) | -1.06 | Shares Out: | 114.12M |
% Price Change (last 4 weeks): | 52.02 |
---|---|
% Price Change (last 13 weeks): | 27.51 |
% Price Change (last 26 weeks): | 87.82 |
% Price Change (last 52 weeks): | 325.65 |
% Price Change (year to date): | 327.73 |
Return on Equity (%): | -17.91 |
---|---|
Return on Assets (%): | -13.14 |
Return on Invested Capital (%): | -14.52 |
Gross Profit Margin (%): | -166.30 |
---|---|
Net Profit Margin (%): | -1490.27 |
Operating Profit Margin (%): | -996.80 |
50-day Moving Average: | $7.33 |
---|---|
200-day Moving Average: | $5.59 |
Avg. Daily Vol. (last 50 days): | 152,143 |
Avg. Daily Vol. (last 200 days): | 830,081 |
52-wk high: | $11.05 |
52-wk low: | $1.61 |
Bid: | $9.75 |
Ask: | $10.00 |
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
|
Mesoblast Ltd.
55 Collins Street Level 38 Melbourne VI 3000 Phone: 61.3.9639.6036 Fax: 61.3.9639.6030 http://www.mesoblast.com |
Earnings (1year) ($): | -0.89 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 4.21 |
Cash Flow ($): | -0.73 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 113.85 |
Price/Book (x): | 1.62 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 1.18 |
---|---|
Current Ratio (x): | 1.18 |
LT Debt/Equity (x): | 21.32 |
Total Debt/Equity (x): | 24.76 |